AU2014212485C1 - Spiro-lactam NMDA receptor modulators and uses thereof - Google Patents
Spiro-lactam NMDA receptor modulators and uses thereof Download PDFInfo
- Publication number
- AU2014212485C1 AU2014212485C1 AU2014212485A AU2014212485A AU2014212485C1 AU 2014212485 C1 AU2014212485 C1 AU 2014212485C1 AU 2014212485 A AU2014212485 A AU 2014212485A AU 2014212485 A AU2014212485 A AU 2014212485A AU 2014212485 C1 AU2014212485 C1 AU 2014212485C1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mmol
- alkyl
- group
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](*)[C@@](*)c1nnc[o]1 Chemical compound C[C@@](*)[C@@](*)c1nnc[o]1 0.000 description 4
- IGIPEOHEUOLQJA-UHFFFAOYSA-N CC(C(c1ncccn1)N(CC1(CCC2C)N2C(CC(C)(C)C)=O)C1=O)O Chemical compound CC(C(c1ncccn1)N(CC1(CCC2C)N2C(CC(C)(C)C)=O)C1=O)O IGIPEOHEUOLQJA-UHFFFAOYSA-N 0.000 description 1
- WVDGSSCWFMSRHN-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C(OC)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C1C(OC)=O)=O WVDGSSCWFMSRHN-UHFFFAOYSA-N 0.000 description 1
- NZQAHYMIQDQGRP-LESKNEHBSA-N CC([C@](CCC1)(C(O)=O)N1C(OC(C)(C)C)=O)O Chemical compound CC([C@](CCC1)(C(O)=O)N1C(OC(C)(C)C)=O)O NZQAHYMIQDQGRP-LESKNEHBSA-N 0.000 description 1
- LHGLBOQYNAIEQR-WCRCJTMVSA-N CC([C@](CCC1)(C(OC)=O)N1C(OC(C)(C)C)=O)O Chemical compound CC([C@](CCC1)(C(OC)=O)N1C(OC(C)(C)C)=O)O LHGLBOQYNAIEQR-WCRCJTMVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757920P | 2013-01-29 | 2013-01-29 | |
US61/757,920 | 2013-01-29 | ||
PCT/US2014/013621 WO2014120784A1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2014212485A1 AU2014212485A1 (en) | 2015-07-30 |
AU2014212485B2 AU2014212485B2 (en) | 2018-04-19 |
AU2014212485C1 true AU2014212485C1 (en) | 2018-10-25 |
Family
ID=50069346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014212485A Active AU2014212485C1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam NMDA receptor modulators and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (5) | US9828384B2 (pt-PT) |
EP (1) | EP2951182B1 (pt-PT) |
JP (1) | JP6531042B2 (pt-PT) |
KR (1) | KR102410989B1 (pt-PT) |
CN (1) | CN105408336B (pt-PT) |
AU (1) | AU2014212485C1 (pt-PT) |
BR (1) | BR112015018089B1 (pt-PT) |
CA (1) | CA2898774C (pt-PT) |
CL (1) | CL2015002122A1 (pt-PT) |
EA (1) | EA032153B1 (pt-PT) |
HK (1) | HK1218418A1 (pt-PT) |
IL (1) | IL240162B (pt-PT) |
MX (1) | MX2015009772A (pt-PT) |
PE (1) | PE20151427A1 (pt-PT) |
PH (1) | PH12015501596A1 (pt-PT) |
SG (1) | SG11201505942YA (pt-PT) |
WO (1) | WO2014120784A1 (pt-PT) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2553968T3 (es) | 2008-09-18 | 2015-12-15 | Northwestern University | Moduladores del receptor NMDA y sus usos |
MX2015009772A (es) * | 2013-01-29 | 2016-05-31 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
CN105229010A (zh) * | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
CN105026401A (zh) | 2013-01-29 | 2015-11-04 | 诺雷克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
KR102280616B1 (ko) | 2013-01-29 | 2021-07-21 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
US9708335B2 (en) | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
CA3024606C (en) | 2016-05-19 | 2019-09-03 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
SG11201900558RA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
CN109661398B (zh) | 2016-08-01 | 2022-07-05 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途 |
AU2017305240B2 (en) * | 2016-08-01 | 2021-12-09 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
SG10202101055VA (en) * | 2016-08-01 | 2021-03-30 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
WO2018026798A1 (en) * | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
WO2019152685A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and methods of using same |
WO2019152681A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
BR112020015666A2 (pt) * | 2018-01-31 | 2021-02-23 | Aptinyx Inc. | moduladores de espiro-lactamas de receptores nmda e usos dos mesmos |
MX2020008107A (es) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
WO2019152688A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
CN113966337B (zh) * | 2020-05-12 | 2024-01-02 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
WO2013014448A1 (en) * | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
US5350769A (en) | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
CA2252417A1 (en) * | 1996-06-07 | 1997-12-11 | Zeneca Limited | Peptide derivatives |
JP2000503860A (ja) | 1996-08-02 | 2000-04-04 | ザイモジェネティクス,インコーポレイティド | 精巣―特異的インシュリン同族体ポリペプチド |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
WO2001036685A2 (en) | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
CA2398250A1 (en) | 2000-02-01 | 2001-08-09 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
WO2001098367A2 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
JP4749715B2 (ja) | 2002-07-05 | 2011-08-17 | ターガセプト,インコーポレイテッド | N−アリールジアザスピロ環式化合物、並びにその製造及び使用方法 |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US7544478B2 (en) | 2003-08-08 | 2009-06-09 | The Burnham Institute | Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors |
US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
ES2428313T3 (es) | 2005-03-24 | 2013-11-07 | Emory University | Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente |
EP1945691A2 (en) | 2005-08-26 | 2008-07-23 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
CN101583612A (zh) | 2006-09-15 | 2009-11-18 | 先灵公司 | 治疗脂质代谢障碍的氮杂环丁酮衍生物 |
JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
WO2010015545A1 (en) | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
EP3488856A1 (en) | 2009-10-05 | 2019-05-29 | Northwestern University | Methods of treating depression and other related diseases |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
KR20190037359A (ko) | 2011-04-27 | 2019-04-05 | 노오쓰웨스턴 유니버시티 | 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 |
US9293690B2 (en) | 2011-06-27 | 2016-03-22 | Koninklijke Philips N.V. | Ultrasound transducer assembly and method of manufacturing the same |
US9708335B2 (en) | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
MX2015009772A (es) | 2013-01-29 | 2016-05-31 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
KR102280616B1 (ko) | 2013-01-29 | 2021-07-21 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
CN105229010A (zh) | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
CN105026401A (zh) | 2013-01-29 | 2015-11-04 | 诺雷克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
-
2014
- 2014-01-29 MX MX2015009772A patent/MX2015009772A/es active IP Right Grant
- 2014-01-29 AU AU2014212485A patent/AU2014212485C1/en active Active
- 2014-01-29 US US14/764,402 patent/US9828384B2/en active Active
- 2014-01-29 BR BR112015018089-2A patent/BR112015018089B1/pt active IP Right Grant
- 2014-01-29 WO PCT/US2014/013621 patent/WO2014120784A1/en active Application Filing
- 2014-01-29 CN CN201480018643.7A patent/CN105408336B/zh active Active
- 2014-01-29 EP EP14703247.8A patent/EP2951182B1/en active Active
- 2014-01-29 CA CA2898774A patent/CA2898774C/en active Active
- 2014-01-29 EA EA201591402A patent/EA032153B1/ru unknown
- 2014-01-29 PE PE2015001568A patent/PE20151427A1/es unknown
- 2014-01-29 SG SG11201505942YA patent/SG11201505942YA/en unknown
- 2014-01-29 KR KR1020157023289A patent/KR102410989B1/ko active IP Right Grant
- 2014-01-29 JP JP2015556099A patent/JP6531042B2/ja active Active
-
2015
- 2015-07-20 PH PH12015501596A patent/PH12015501596A1/en unknown
- 2015-07-27 IL IL240162A patent/IL240162B/en active IP Right Grant
- 2015-07-29 CL CL2015002122A patent/CL2015002122A1/es unknown
-
2016
- 2016-06-06 HK HK16106443.2A patent/HK1218418A1/zh unknown
-
2017
- 2017-08-08 US US15/671,409 patent/US20180179218A1/en not_active Abandoned
-
2018
- 2018-03-28 US US15/938,040 patent/US20180215767A1/en not_active Abandoned
- 2018-05-02 US US15/968,976 patent/US20180244680A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/919,438 patent/US20210155632A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
WO2013014448A1 (en) * | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Non-Patent Citations (1)
Title |
---|
MACIAS, A. ET AL., Journal of Organic Chemistry, 2006, 71 (20), pages 7721-7730. * |
Also Published As
Publication number | Publication date |
---|---|
CN105408336B (zh) | 2018-06-26 |
JP2016506959A (ja) | 2016-03-07 |
AU2014212485B2 (en) | 2018-04-19 |
US20150368252A1 (en) | 2015-12-24 |
US9828384B2 (en) | 2017-11-28 |
MX2015009772A (es) | 2016-05-31 |
PH12015501596A1 (en) | 2015-10-19 |
PE20151427A1 (es) | 2015-10-10 |
US20180179218A1 (en) | 2018-06-28 |
EP2951182A1 (en) | 2015-12-09 |
US20180244680A1 (en) | 2018-08-30 |
CN105408336A (zh) | 2016-03-16 |
EA201591402A1 (ru) | 2015-12-30 |
JP6531042B2 (ja) | 2019-06-12 |
IL240162B (en) | 2020-08-31 |
NZ709872A (en) | 2020-09-25 |
US20210155632A1 (en) | 2021-05-27 |
EP2951182B1 (en) | 2020-03-18 |
WO2014120784A1 (en) | 2014-08-07 |
CA2898774C (en) | 2021-07-13 |
IL240162A0 (en) | 2015-09-24 |
KR102410989B1 (ko) | 2022-06-17 |
HK1218418A1 (zh) | 2017-02-17 |
CA2898774A1 (en) | 2014-08-07 |
CL2015002122A1 (es) | 2015-12-18 |
EA032153B1 (ru) | 2019-04-30 |
BR112015018089B1 (pt) | 2022-09-20 |
KR20150110788A (ko) | 2015-10-02 |
US20180215767A1 (en) | 2018-08-02 |
BR112015018089A2 (pt) | 2017-07-18 |
AU2014212485A1 (en) | 2015-07-30 |
SG11201505942YA (en) | 2015-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014212485C1 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
US10273239B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
US10196401B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
EP2951185B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP2951183B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP2951186A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
NZ709872B2 (en) | Spiro-lactam nmda receptor modulators and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: APTINYX, INC. Free format text: FORMER APPLICANT(S): NAUREX, INC. |
|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 JUL 2018 |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 10 JUL 2018 |
|
FGA | Letters patent sealed or granted (standard patent) |